TOSHIBA-CORPORATION
Toshiba Corporation (TOKYO: 6502) today announced that Institutional Shareholder Services Inc. (“ISS”), the leading independent proxy advisory firm, has recommended that shareholders vote for all 12 of Toshiba’s highly-qualified director nominees at the Company’s Ordinary General Meeting of Shareholders for the 181st Fiscal Period, to be held on July 31, 2020.
As ISS stated in its independent report1 : “…our analysis and engagement with the company suggest that the recently reconstituted board is appropriately focused on the key issues impacting Toshiba. As such, additional change at the board level does not appear necessary.”
Toshiba's Board of Directors stated, “We are pleased ISS has recommended that Toshiba shareholders vote for all of our highly-qualified and experienced Directors. ISS’ support further validates the progress that we made last year to refresh our Board with shareholder input and our strong belief that Toshiba’s slate of directors has the right mix of skills, experiences and new perspectives to provide independent oversight of the continued execution of our transformational Toshiba Next Plan (TNP). Through the TNP, we expect to deliver sustainable long-term growth and value to all of our shareholders. We encourage all of our shareholders to vote for our director nominees at our upcoming Ordinary General Meeting of Shareholders.”
In making its recommendation, ISS noted:
- “The company is appointing a new independent chairman, and seven of the other 9 independent directors have only been at the company for one year; the two remaining independent directors have tenures of two and four years, respectively. […] The current directors generally appear to have relevant and diverse credentials.”
- “[…] the company seems to have taken appropriate actions in recent years, and the board’s overhaul last year suggests it will maintain the course. […] the board – particularly the recently elected foreign directors – appear to be appropriately focused in their oversight.”
- “It is also worth noting that while 3D Investment is seeking to replace two directors, Effissimo is proposing to add three nominees to the 12-member slate nominated by the company. Such an increase raises questions as to whether a 15-member board could become less effective as different factions compete over disparate priorities.”
The Board unanimously recommends that Toshiba shareholders to vote “FOR” director candidates 1-12 and “AGAINST” candidates 13-17, as listed in our Convocation Notice.
Institutional investors and those shareholders holding shares through a custodian or intermediary should directly contact their custodian or voting platform provider for proxy voting instructions. Please be mindful that custodial vote deadlines may be very much earlier than the market deadline of 17:15 JST on 30 July 2020. Shareholders are encouraged to submit their proxy votes online through the electronic voting platform ProxyEdge operated by ICJ, Inc., if they have applied in advance to do so. Please refer to the Convocation Notice for further guidance, which can be found at https://www.toshiba.co.jp/about/ir/en/stock/meeting.htm .
1 Permission to quote from the ISS report was neither sought nor obtained.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005533/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe6.11.2025 08:00:00 CET | Press release
Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (ustekinumab) by the European Commission (EC) in April 2024. PYZCHIVA is currently approved for the treatment of adults and paediatric patients from the age of 6 years and older with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, adults with moderate to severely active Crohn’s disease. “This is a significant milestone for patients living with autoimmune diseases as we are making a step forward in improving access to this important biologic medicine for healthcare systems, pr
SES Delivers Solid 9 Months and Q3 2025 Results6.11.2025 07:30:00 CET | Press release
SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the nine months and three months ended 30 September 2025 with solid operational and financial performance. Solid 9 months 2025 financial performance on a reported basis (Intelsat fully consolidated from 17 July 2025) Revenue of €1,747 million (+19.8% yoy(1)) and Adjusted EBITDA(2) of €849 million (+11.0% yoy(1)) Networks (+36.3% yoy(1)) supported by growth in Aviation and Government; Media (+0.7% yoy(1)) with important new long-term renewals signed Solid progress with company integration and synergy execution since Day 1 of transaction closure €1.4 billion of new business and contract renewals signed YTD 2025 – with a total combined gross backlog of €7.1 billion O3b mPOWER satellites 9 &10 successfully launched on 22 July, expected to be in service beginning 2026 – boosting O3b mPOWER network capacity and resilience Collected c.$87 million regarding insurance claim for O3b mPOWER satellites 1-4 w
Transition Industries and Mitsubishi Gas Chemical Sign Agreement for the Purchase and Sale of Ultra-Low Carbon Methanol6.11.2025 05:00:00 CET | Press release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, signed a long-term methanol sales and purchase agreement with Mitsubishi Gas Chemical Company, Inc. (MGC) for the offtake of ultra-low carbon methanol. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105695992/en/ Masahiko Naito, Division Director of Mitsubishi Gas Chemical and Rommel Gallo, CEO of Transition Industries sign agreement in Tokyo, November 6, 2025 Under the Agreement, which will become effective upon the Project’s Final Investment Decision (FID), Transition Industries will supply MGC approximately 1 million MT per annum of ultra-low carbon methanol from its Pacifico Mexinol project, a 6,130 MT per day methanol production facility near Topolobampo, Sinaloa, Mexico, expected to be in operation in 2029. Transition Industries is jointly developing Pacifico Mexinol with the International Finance Corpora
Kinaxis Announces Normal Course Issuer Bid5.11.2025 23:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 12, 2025 and ending November 11, 2026, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,403,042 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 31, 2025. As of the close of business on October 31, 2025, the Company had 28,060,844 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased p
Hyper® Wins Dual CES 2026 Innovation Awards® for its Breakthrough Tech Accessories5.11.2025 22:45:00 CET | Press release
Hyper’s HyperSpace™ Trackpad Pro and HyperDrive® Next USB4 M.2 PCIe Enclosure named as CES Innovation Awards® 2026 Honorees Hyper®, a leader in mobile tech accessories for creators and power users, today announced it has been honored with two CES2026 Innovation Awards® in the Consumer Peripherals and Accessories category. These awards reflect Hyper’s mission to build breakthrough solutions that help users create, connect, and go beyond the limits of their devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105297377/en/ CES Innovation Awards® 2026 Honorees: HyperSpace™ Trackpad Pro and HyperDrive® Next redefine haptics, personalization, and next-gen USB4 V2 speed. The CES Innovation Awards program is an annual competition that honors the most innovative, new products in consumer technology, recognizing top innovations across multiple categories. “For 20 years, Hyper has led the tech accessory space with industry-defin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
